BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Episodes
305 episodes
Ep. 295 - Bio€quity Europe 2025 Preview
This year’s Bio€quity Europe conference — the 25th edition of the event — will focus on what’s next for Europe amid biotech’s current complex moment, Editor in Chief Simone Fishburn said on a special edition of the BioCentury This Week...
•
Season 6
•
Episode 295
•
28:34
Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing
Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid tumors. On the latest BioCentury This Week podcast, BioCentury's editors zero in on p...
•
Season 6
•
Episode 294
•
30:35
Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs
Belief in tau — both as a target and surrogate endpoint — for Alzheimer’s is building among leaders in the field. On the latest BioCentury This Week podcast, Executive Editor Selina Koch
•
Season 6
•
Episode 293
•
31:05
Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview
Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare autoimmune neuromuscular disease coming at this month’s American Academy of Neurology. On a speci...
•
Season 6
•
Episode 292
•
25:51
Ep. 291 - Grand Rounds - U.S. Preview
The academia-industry interface is more important than ever for sustaining biomedical innovation’s forward momentum, even as the Trump administration injects turbulence into academic fundi...
•
Season 6
•
Episode 291
•
31:02
Ep. 290 - Biotech Survey Sees Tough Days Ahead. Plus: FDA, China Speed
The biotech community is reeling, fearful and furious about the fallout of tariff, FDA and NIH policies, according to BioCentury’s newly released Risk Sentiment survey...
•
Season 6
•
Episode 290
•
38:10
Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA
FDA’s plan to move away from animal toxicity testing could expedite INDs and cut costs for biopharma companies, while helping the U.S. maintain its position as a clinical research hub. On ...
•
Season 6
•
Episode 289
•
36:55
Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview
Loss of leadership, cuts to staffing and a proposed reorganization at FDA have heightened biotech risk amid an already turbulent mac...
•
Season 6
•
Episode 288
•
26:34
Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI
Biotech indexes are tumbling after one of FDA’s last veteran leaders was pushed out by HHS Secretary RFK Jr. and the threat of tariffs weigh on a key biotech index. On the latest BioCentury This Week podcast, BioCentury’s editors discu...
•
Season 6
•
Episode 287
•
25:46
Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs
European venture firm Sofinnova Partners is expanding the reach of its Biovelocita accelerator beyond Italy to stretch across the greater continent. On the latest BioCentury This Week podcast, BioCentury’s editors
•
Season 6
•
Episode 286
•
24:30
Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play
BIO is engaging with President Donald Trump to protect and improve FDA. It’s also hoping biopharmas can dodge tariffs and find paths to modify the Inflation Reduction Act and reinstate pediatric priority review vouchers. On the latest BioCentur...
•
Season 6
•
Episode 285
•
28:26
Ep. 284 - Takeaways from the East-West Summit
While the culling of companies in the biotech bear market may have yet to subside, creative cross-border deal-making on innovative assets is spreading across Asia’s Arc of Innovation. Sciwind Biosciences Co. Ltd.’s Jing Shu and A*Star’s Lisa Oo...
•
Season 6
•
Episode 284
•
41:27
Ep. 283 - Makary’s FDA Agenda, Amylin in Obesity and Life After DEI
The almost certain confirmation of Marty Makary as FDA commissioner this month will cap a transition marked by internal upheaval and political infighting. On the latest BioCentury This Week podcast, BioCentury’s editors discuss Thursday’s
•
Season 6
•
Episode 283
•
31:30
Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity
The track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform companies should validate their technology on established targets or pursue new ones. On the la...
•
Season 6
•
Episode 282
•
23:46
Ep. 281 - Roche Reboot and 5 Things on Trump 2.0
Once pharma’s oncology powerhouse, Roche is charting a new course that extends beyond its traditional stronghold in cancer therapeutics. On the latest BioCentury This Week podcast...
•
Season 6
•
Episode 281
•
22:12
Ep. 280 - China Competition. Plus: FDA Firings and Biotech IPOs
Rather than fretting over increasing competition from Chinese life sciences companies, biotechs in the U.S. should rise to the challenge and learn from their competitors. On the latest BioCentury This Week podcast, BioCentury’s editors...
•
Season 6
•
Episode 280
•
27:52
Ep. 279 - East-West Summit Preview
Western VCs are paying more attention than ever to innovation emerging from Asia — from antibody-drug conjugates to bispecifics, AI and beyond — as the NewCo Model becomes the latest trend to bridge talent, assets and venture money across the P...
•
Season 6
•
Episode 279
•
29:54
Ep. 278 - Trump 2.0’s Impact on FDA, NIH. Plus: Precision Medicine
White House plans to slash FDA and NIH risk decimating two agencies at the core of U.S. biomedical innovation. On the latest BioCentury This Week podcast, BioCentury’s editors assess<...
•
Season 6
•
Episode 278
•
26:14
Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug
The boom in the creation of companies that were launched in the West based on assets sourced in Asia signals China’s galloping speed of innovation. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the “
•
Season 6
•
Episode 277
•
25:03
Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler
Psychiatric drug development has had major wins over the past year-and-a-half — think Karuna Pharmaceuticals' $14 billion takeout by Bristol Myers Squibb and the subsequent launch of a new schizophrenia therapy — but targeted neuropsychiatric d...
•
Season 6
•
Episode 276
•
21:07
Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH
BioCentury’s analysis of the technologies behind last year’s biotech series A raisers sees progress in nanoparticles, CAR cell therapies, degraders and antibody-drug conjugates. On the latest BioCentury This Week podcast, BioCentury’s ...
•
Season 6
•
Episode 275
•
33:09
Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI
With political uncertainty overshadowing market sentiment going into 2025, BioCentury’s editorial team assesses the bull and bear arguments for biotech in the New Year on the BioCentury This Week podcast’s
•
Season 6
•
Episode 274
•
36:21
Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds
Sunshine and a stream of deals brightened the mood at this year’s J.P. Morgan Healthcare Conference, offering a pleasant counterpoint to continued pessimism over the state of the capital markets. On the latest BioCentury This Week podc...
•
Season 6
•
Episode 273
•
22:21
Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma
J&J’s $14.6 billion takeout of neurology play Intra-cellular Therapies headlined a buzzy start to the J.P. Morgan Healthcare Conference, where a flurry of deal announcements recalled the conference’s pre-pandemic days. On the latest Bio...
•
Season 6
•
Episode 272
•
27:29
